ROTH Capital Partners, LLC expects to receive or intends to seek...

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business
relationships with the covered companies mentioned in this report in the next three months. The material, information and
facts discussed in this report other than the information regarding ROTH Capital Partners, LLC and its affiliates, are from
sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This report should not be used
as a complete analysis of the company, industry or security discussed in the report. Additional information is available upon
request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this report are
subject to change without notice. An investment in the stock may involve risks and uncertainties that could cause actual
results to differ materially from the forward-looking statements. Additionally, an investment in the stock may involve a high
degree of risk and may not be suitable for all investors. No part of this report may be reproduced in any form without the
express written permission of ROTH. Copyright 2020. Member: FINRA/SIPC.

It is always good to read the disclaimers when these reports are issued...In other words Roth are being paid to issue
this analysis based on information supplied to it, this is standard procedure.....
This is not meant to be a criticism by me but it is good to be aware of....
Very good report and will reach a wider audience than just Imugene company releases....
Biotechs need this sort of promotion...